KR101922903B1 - Method for screening natural product-derived antineurodegenerative ingredients - Google Patents
Method for screening natural product-derived antineurodegenerative ingredients Download PDFInfo
- Publication number
- KR101922903B1 KR101922903B1 KR1020160029678A KR20160029678A KR101922903B1 KR 101922903 B1 KR101922903 B1 KR 101922903B1 KR 1020160029678 A KR1020160029678 A KR 1020160029678A KR 20160029678 A KR20160029678 A KR 20160029678A KR 101922903 B1 KR101922903 B1 KR 101922903B1
- Authority
- KR
- South Korea
- Prior art keywords
- tdp
- natural material
- protein
- cells
- cytoplasm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000012216 screening Methods 0.000 title claims abstract description 27
- 229930014626 natural product Natural products 0.000 title claims 4
- 230000002555 anti-neurodegenerative effect Effects 0.000 title description 3
- 239000004615 ingredient Substances 0.000 title description 2
- 239000005445 natural material Substances 0.000 claims abstract description 49
- 210000004295 hippocampal neuron Anatomy 0.000 claims abstract description 41
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 30
- 230000002776 aggregation Effects 0.000 claims abstract description 19
- 238000004220 aggregation Methods 0.000 claims abstract description 19
- 230000004083 survival effect Effects 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 12
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims abstract description 6
- 101710096438 DNA-binding protein Proteins 0.000 claims abstract description 6
- 230000002103 transcriptional effect Effects 0.000 claims abstract description 5
- 230000004044 response Effects 0.000 claims abstract description 4
- 230000035899 viability Effects 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 41
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 20
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 14
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 14
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 14
- 229960001285 quercetin Drugs 0.000 claims description 14
- 235000005875 quercetin Nutrition 0.000 claims description 14
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 claims description 13
- 230000015271 coagulation Effects 0.000 claims description 10
- 238000005345 coagulation Methods 0.000 claims description 10
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 5
- 239000003207 proteasome inhibitor Substances 0.000 claims description 5
- -1 sizandrine Chemical compound 0.000 claims description 5
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 abstract 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 13
- 238000009825 accumulation Methods 0.000 description 12
- 230000004770 neurodegeneration Effects 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 208000015122 neurodegenerative disease Diseases 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002073 fluorescence micrograph Methods 0.000 description 8
- 230000004845 protein aggregation Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229930193974 gastrodin Natural products 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229930193195 schizandrin Natural products 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026517 Lamin-B1 Human genes 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 241000736075 Schisandra Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- WFDMJQGKSLWSMR-IYAPHFDMSA-N [(2R,3R,4R,5R)-2-(6-amino-6-butanoyl-8H-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] butanoate Chemical compound CCCC(=O)O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(C(=O)CCC)(N)C2=NC1 WFDMJQGKSLWSMR-IYAPHFDMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108010052263 lamin B1 Proteins 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
본 발명은 (a) 천연물 소재에 대한 마우스 유래 해마신경세포의 생존율을 평가하여, 상기 해마신경세포의 생존율에 영향을 미치지 않는 상기 천연물 소재의 농도를 결정하는 단계, (b) 상기 결정된 천연물 소재의 농도에 대한 상기 해마신경세포의 세포질내에 존재하는 트랜스액티브 리스폰스 DNA-결합 단백질 43(TDP-43)의 응집율을 평가하여, 천연물 소재를 스크리닝하는 단계, 및 (c) 항원-항체반응을 이용하여, 상기 스크리닝된 천연물 소재에 대한 해마신경세포의 세포질 및 핵내의 TDP-43 발현량을 평가하는 단계를 포함하는 항신경변성 천연물 소재의 스크리닝 방법에 관한 것이다.The present invention relates to a method for evaluating the survival rate of hippocampal neurons, comprising the steps of: (a) evaluating the survival rate of mouse-derived hippocampal neurons for a natural material, and determining the concentration of the natural material not affecting the viability of the hippocampal neurons; (TDP-43) present in the cytoplasm of the hippocampal neuron, and screening the natural material; and (c) using the antigen-antibody reaction to assess the aggregation rate of the transcriptional response DNA-binding protein 43 , And evaluating the amount of TDP-43 expression in the cytoplasm and nucleus of hippocampal neurons for the screened natural material.
Description
본 발명은 항신경변성 천연물 소재의 스크리닝 방법에 관한 것으로, 보다 상세하게는 (a) 천연물 소재에 대한 마우스 유래 해마신경세포의 생존율을 평가하여, 상기 해마신경세포의 생존율에 영향을 미치지 않는 상기 천연물 소재의 농도를 결정하는 단계, (b) 상기 결정된 천연물 소재의 농도에 대한 상기 해마신경세포의 세포질내에 존재하는 트랜스액티브 리스폰스 DNA-결합 단백질 43(TDP-43)의 응집율을 평가하여, 천연물 소재를 스크리닝하는 단계, 및 (c) 항원-항체반응을 이용하여, 상기 스크리닝된 천연물 소재에 대한 해마신경세포의 세포질 및 핵내의 TDP-43 발현량을 평가하는 단계를 포함하는 항신경변성 천연물 소재의 스크리닝 방법에 관한 것이다.The present invention relates to a method for screening an anti-neural degenerate natural material, and more particularly, to a method for screening a natural neural material, which comprises (a) evaluating the survival rate of a mouse-derived hippocampal neuron for a natural material, (B) evaluating the aggregation rate of the transcriptional response DNA-binding protein 43 (TDP-43) present in the cytoplasm of the hippocampal neuron to the determined concentration of the natural material, , And (c) evaluating the amount of TDP-43 expression in the cytoplasm and nucleus of hippocampal neurons for the screened natural material using an antigen-antibody reaction. Screening method.
신경변성 질환 환자의 신경세포가 기능을 잃거나 사멸하는 원인에 대해서는 몇가지 가설이 존재하지만 아직까지 뚜렷한 원인이나 치료 방법이 제시되지 못하는 실정이다. There are several hypotheses about the causes of neuronal loss or death in patients with neurodegenerative diseases. However, no definite cause or treatment method has been proposed yet.
근위축측삭경화증 및 전두측두엽 치매 환자의 병리적인 특징으로 세포질 내 유비퀴틴(ubiquitin)화된 트랜스액티브 리스폰스 DNA-결합 단백질 43(TDP-43) 단백질 축적이 발견되면서, 또 하나의 새로운 신경변성 질환의 원인으로 제시되고 있다.(TDP-43) protein accumulation in the cytoplasm of ubiquitinated transactivated DNA-binding protein 43 (DDP-43) in patients with atrophic lateral sclerosis and frontotemporal dementia as a cause of another neurodegenerative disease Is presented.
정상 TDP-43은 핵 내에 위치하지만 병적인 상태에서는 세포질 내에 존재한다. 신경세포 내 TDP-43 단백질의 비정상적 위치로 인해 신경세포에서 갖는 정상적인 기능이 상실되고, 그에 따라 신경세포의 기능부전 및 사멸이 유도됨에 따라, 신경변성질환이 나타나게 된다는 것이다. Normal TDP-43 is located in the nucleus but is present in the cytoplasm in pathological conditions. The abnormal location of the TDP-43 protein in the neuron leads to the loss of normal function of the neuron, which leads to neuronal dysfunction and death, resulting in neurodegenerative disease.
TDP-43 단백질 돌연변이를 유도한 세포주 및 제브라피쉬 배아(zebrafish embryo)에서 운동신경의 결함 또는 독성을 보이며, TDP-43의 과도한 발현은 신경세포의 사멸 및 운동신경의 손상을 유도하였으며, 특히 C-말단의 분절(fragment)은 세포내 독성을 나타내어 신경세포의 사멸에 관여한다 (Human molecular genetics, 19, 671-683, 2010; Molecular Therapy 17,607-613, 2009; Proceedings of the National Academy of Sciences. 106,7607-7612, 2009 등). The TDP-43 protein mutation induces apoptosis and motor neuron deficiency in the zebrafish embryo, and excessive expression of TDP-43 induces neuronal death and motor nerve damage, Terminal fragments exhibit intracellular toxicity and are involved in the death of nerve cells (Human molecular genetics, 19, 671-683, 2010; Molecular Therapy 17, 607-613, 2009; Proceedings of the National Academy of Sciences. 106, 7607-7612, 2009, etc.).
이러한 연구 보고는 변성된 TDP-43 단백질이 신경변성 질환을 유발한다는 가설의 근거로 제시될 수 있다. 이에 따라 새로운 신경변성 질환의 바이오마커인 TDP-43 단백질을 이용하여 효과가 있는 기능성 성분을 탐색하는 것은 신경변성 질환의 예방 및 치료에 도움을 줄 수 있는 소재를 개발하기 위한 기초 연구가 될 수 있다. These studies can be suggested as a basis for the hypothesis that denatured TDP-43 protein induces neurodegenerative diseases. Therefore, exploring effective functional components by using TDP-43 protein, a biomarker of new neurodegenerative diseases, can be a basic research for developing materials capable of preventing and treating neurodegenerative diseases .
TDP-43 단백질은 414개의 아미노산으로 이루어진 DNA/RNA 결합 단백질로 분자량은 43 kDa이다. TDP-43 단백질은 인간 면역결핍 바이러스 타입 1(HIV-1)의 TAR DNA 에 결합하여 유전자의 전사를 억제하는 단백질로 처음 밝혀졌다 (J. Virol, 69, 3584-96, 1995). The TDP-43 protein is a 414 amino acid DNA / RNA binding protein with a molecular weight of 43 kDa. The TDP-43 protein was first identified as a protein that binds to TAR DNA of human immunodeficiency virus type 1 (HIV-1) and inhibits gene transcription (J. Virol, 69, 3584-96, 1995).
그 이후에 TDP-43 단백질은 유전자의 전사조절, 선택적 스플라이싱, mRNA의 운반 등의 세포 내 생리활성에 관여하는 것으로 나타났다 (Int J Clin Exp Pathol, 4, 147-55, 2011; Journal of Biological Chemistry, 276, 3633-36343, 2001). Since then, the TDP-43 protein has been implicated in intracellular physiological activities such as transcriptional regulation of genes, selective splicing, and mRNA delivery (Int J Clin Exp Pathol, 4, 147-55, 2011; Journal of Biological Chemistry, 276, 3633-36343, 2001).
2006년 비타우병증의 전두측두엽치매환자와 ALS 환자의 신경세포에서 관찰되는 유비퀴틴 양성 봉입체의 주요 단백질이 TDP-43 이라는 것이 밝혀지면서, 이 단백질과 다른 신경변성 질환과의 관련성에 대해 연구가 진행되고 있다 (Biochemical and biophysical research communications, 351, 602-611, 2006; Annals of neurology, 61, 435-445, 2007; Neuropathology, 29, 566-73, 2009 등). In 2006, we found that TDP-43 is the major protein of the ubiquitin-positive inclusion body in the frontal dementia patients with dichotomous frontal lobe dementia and ALS patients, and the relationship between this protein and other neurodegenerative diseases has been studied (Biochemical and biophysical research communications, 351, 602-611, 2006; Annals of neurology, 61, 435-445, 2007; Neuropathology, 29, 566-73, 2009).
정상세포에서 TDP-43은 주로 핵내에서 발현하는 단백질이지만, 세포가 스트레스 환경에 놓이게 되면 활성화된 카스파제(caspase)에 의해 TDP-43 단백질이 분할되고, TDP-43 C-말단이 인산화되면서 유비퀴틴화된 후, 프로테아좀에 의해 분해되게 되는데, 인산화된 TDP-43이 분해, 제거되지 않고 세포질 내 응집, 축적되면 신경세포가 기능을 잃거나 사멸하게 된다 (Science, 314, 130-133, 2006; Experimental neurology, 237, 90-95, 2012 등). In normal cells, TDP-43 is mainly a protein expressed in the nucleus. However, when the cell is placed in a stressed environment, the TDP-43 protein is cleaved by the activated caspase, and TDP-43 C- (TDP-43) is degraded and removed, and aggregation and accumulation in the cytoplasm results in loss of function or death of the nerve cell (Science, 314, 130-133, 2006; Experimental neurology, 237, 90-95, 2012, etc.).
그래서, 신경퇴행성 환자의 신경세포에서 TDP-43단백질의 세포질내 inclusion 형성, 불용성(poorly soluble or insolubility), 과인산화(hyperphosphorylated), 유비퀴틴화(ubiquitinated), 분할(cleaved into small fragment)의 특성을 보인다 (Nature Reviews Neurology, 6, 211-220, 2010; Neurosignals, 16, 41-51, 2008). Thus, the neuronal cells of neurodegenerative patients exhibit the properties of cytoplasmic inclusion, poorly soluble or insolubility, hyperphosphorylated, ubiquitinated, and cleaved into small fragments of TDP-43 protein (Nature Reviews Neurology, 6, 211-220, 2010, Neurosignals, 16, 41-51, 2008).
한국공개특허 제10-2009-0046576호에는 (a) 아밀로이드 단백질이 결합되어 있는 고체기판 상에 아밀로이드 단백질을 침착시키는 단계, (b) 상기 아밀로이드 단백질 침착물이 형성된 고체기판 상에서 퇴행성 신경질환 치료제 후보물질의 존재 하에 신경세포를 배양하는 단계, 및 (c) 배양된 신경세포의 활성을 측정하여, 상기 활성을 증진 또는 유지시키는 신약 후보물질을 퇴행성 신경질환 치료제로 스크리닝하는 단계를 포함하는 퇴행성 신경질환 치료제의 스크리닝 방법이 개시되어 있다. Korean Patent Laid-Open No. 10-2009-0046576 discloses a method for preparing a pharmaceutical composition comprising the steps of (a) depositing an amyloid protein on a solid substrate to which an amyloid protein is bound, (b) And (c) measuring the activity of the cultured neuron and screening the candidate drug candidate for promoting or maintaining the activity with a therapeutic agent for degenerative neurological disease, comprising the steps of: Is disclosed.
또한, 한국공개특허 제10-2015-0015226호에는 세포질과 신경세포 가지에 비정상적으로 위치하거나, 정상 TDP-43의 기능 소실 유도하여 신경세포의 비정상적 구조 변화 일으키는 TDP-43 미스센스 돌연변이를 포함하는 퇴행성 신경계 질환 진단용 마커가 개시되어 있다.Korean Patent Laid-Open No. 10-2015-0015226 discloses a method for producing a TDP-43 degenerative disorder including TDP-43 mismatch mutation that abnormally locates in the cytoplasm and nerve cell branches, induces abnormal loss of normal TDP-43, A marker for diagnosing neurological diseases is disclosed.
그러나, 상기 한국공개특허 제10-2015-0015226호는 항신경변성 소재의 스크리닝 방법이라는 점에서는 본 발명과 동일하지만, 상기 종래기술은 아밀로이드 단백질의 침착을 억제시키는 생리활성 물질을 스크리닝함에 대하여, 본 발명은 TDP-43 단백질의 응집을 억제시키는 생리활성 물질을 스크리닝한다는 점에서, 양 발명은 스크리닝의 대상이 전혀 상이하다.However, the Korean Patent Laid-Open No. 10-2015-0015226 is the same as the present invention in that it is a screening method of an anti-neuron-degenerate material. However, the prior art screened the physiologically active substance which inhibits deposition of amyloid protein, Since the invention screened for a physiologically active substance which inhibits aggregation of TDP-43 protein, both inventions are completely different from each other in screening.
또한, 상기 한국공개특허 제10-2015-0015226호는 신경세포의 비정상적 구조 변화 일으키는 TDP-43 미스센스 돌연변이를 포함하는 퇴행성 신경계 질환 진단용 마커에 관한 것으로서, TDP-43 단백질을 대상으로 하고 있다는 점을 제외하고는 본 발명과 구성이 전혀 상이하다.Korean Patent Laid-Open No. 10-2015-0015226 discloses a marker for diagnosing degenerative neurological diseases including a TDP-43 mismatch mutation which causes abnormal structural change of nerve cells. The present invention and the configuration are completely different.
본 발명은 상기와 같은 종래기술의 문제점을 해결하기 위한 것으로서, 본 발명의 목적은 해마신경세포에 TDP-43 단백질의 응집을 유도하여 신경변성질환에 효과가 있는 천연물 소재에 대한 TDP-43 축적 억제능을 확인함으로써, TDP-43 축적 질환 관련 인지능 또는 기억력 개선 타겟팅 소재를 효과적으로 스크리닝하는 방법을 제공하는 것이다. Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above problems occurring in the prior art, and it is an object of the present invention to provide a method for inhibiting accumulation of TDP-43 on a natural material effective for neurodegenerative diseases by inducing aggregation of TDP- To provide a method for effectively screening for TDP-43 accumulation-related cognitive or memory-enhancing targeting material.
본 발명은 상기와 같은 과제를 해결하기 위하여, (a) 천연물 소재에 대한 마우스 유래 해마신경세포의 생존율을 평가하여, 상기 해마신경세포의 생존율에 영향을 미치지 않는 상기 천연물 소재의 농도를 결정하는 단계, (b) 상기 결정된 천연물 소재의 농도에 대한 상기 해마신경세포의 세포질내에 존재하는 트랜스액티브 리스폰스 DNA-결합 단백질 43(TDP-43)의 응집율을 평가하여, 천연물 소재를 스크리닝하는 단계, 및 (c) 항원-항체반응을 이용하여, 상기 스크리닝된 천연물 소재에 대한 해마신경세포의 세포질 및 핵내의 TDP-43 발현량을 평가하는 단계를 포함하는 항신경변성 천연물 소재의 스크리닝 방법을 제공한다.(A) evaluating the survival rate of a mouse-derived hippocampal neuron for a natural material and determining the concentration of the natural material not affecting the survival rate of the hippocampal neuron, (b) evaluating the aggregation rate of the transcriptional response-DNA-binding protein 43 (TDP-43) present in the cytoplasm of the hippocampal neuron to the determined concentration of the natural material, screening the natural material and c) evaluating the expression level of TDP-43 in the cytoplasm and nucleus of hippocampal neuron cells against the screened natural material using an antigen-antibody reaction.
본 발명의 신경변성 천연물 소재의 스크리닝 방법에 의하면, in vitro에서 해마신경세포의 세포질내 TDP-43 단백질 응집억제 효과가 있는 천연물 소재들을 신속히 선별할 수 있는 장점이 있다.According to the screening method of the neurodegenerative natural material of the present invention, it is possible to rapidly select the natural material having the effect of inhibiting TDP-43 protein aggregation in the cytoplasm of hippocampal neurons in vitro.
도 1은 해마신경세포 HT-22 세포주에 대한 천연물 소재에 따른 세포 생존율을 나타낸 것이다.
도 2는 가스트로딘의 TDP-43 응집 억제 효과에 대한 형광이미지 평가 결과를 나타낸 것이다.
도 3은 시잔드린의 TDP-43 응집 억제 효과에 대한 형광이미지 평가 결과를 나타낸 것이다.
도 4는 퀘세틴의 TDP-43 응집 억제 효과에 대한 형광이미지 평가 결과를 나타낸 것이다.
도 5는 형광이미지 평가로 스크리닝된 천연물 소재 대한 TDP 43 축적 억제 항원-항체반응 검증 평가 결과를 나타낸 것이다. FIG. 1 shows cell viability of hippocampal neuron HT-22 cell line according to natural material.
FIG. 2 shows fluorescence image evaluation results of the TDP-43 aggregation inhibitory effect of gastronidin.
FIG. 3 shows fluorescence image evaluation results of TDP-43 aggregation inhibitory effect of thymidine.
Figure 4 shows fluorescence image evaluation results of quercetin against TDP-43 aggregation inhibitory effect.
FIG. 5 shows the results of the
본 발명은 (a) 천연물 소재에 대한 마우스 유래 해마신경세포의 생존율을 평가하여, 상기 해마신경세포의 생존율에 영향을 미치지 않는 상기 천연물 소재의 농도를 결정하는 단계, (b) 상기 결정된 천연물 소재의 농도에 대한 상기 해마신경세포의 세포질내에 존재하는 트랜스액티브 리스폰스 DNA-결합 단백질 43(TDP-43)의 응집율을 평가하여, 천연물 소재를 스크리닝하는 단계, 및 (c) 항원-항체반응을 이용하여, 상기 스크리닝된 천연물 소재에 대한 해마신경세포의 세포질 및 핵내의 TDP-43 발현량을 평가하는 단계를 포함하는 항신경변성 천연물 소재의 스크리닝 방법에 관한 것이다.The present invention relates to a method for evaluating the survival rate of hippocampal neurons, comprising the steps of: (a) evaluating the survival rate of mouse-derived hippocampal neurons for a natural material, and determining the concentration of the natural material not affecting the viability of the hippocampal neurons; (TDP-43) present in the cytoplasm of the hippocampal neuron, and screening the natural material; and (c) using the antigen-antibody reaction to assess the aggregation rate of the transcriptional response DNA-binding
본 발명의 상기 항신경변성 천연물 소재의 스크리닝 방법에서, 상기 천연물 소재는 가스트로딘, 시잔드린 및 퀘세틴으로 이루어진 군에서 선택되는 1종 이상일 수 있다. In the method for screening the anti-neuronigenic natural material of the present invention, the natural material may be at least one selected from the group consisting of gastrodine, sizandrine, and quercetin.
항신경변성 효과가 있는 대표적인 국내 천연물 소재로는 시잔드린, 가스트로딘, 퀘세틴 등이 있으며, 시잔드린 (schizandrin)은 오미자 (Schisandra chinensis (Turcz.) Baill)에 포함되어 있는 기능성 성분으로서, 글르타메이트에 의해 유도된 대뇌피질 세포의 세포자살(apoptosis) 억제 (Molecules, 18, 354-372, 2012 등), β-아밀로이드에 의해 유도된 신경독성 보호(Phytotherapy Research, 25, 435-443, 2011 등), 항염증 효과(International immunopharmacology, 17, 415-426, 2013), β-아밀로이드 1-42 생성 억제 효과(Acta pharmaceutica Sinica, 41, 1136-1140, 2006) 등에 의해 치매를 비롯한 신경퇴행성 질환의 예방효과가 보고되어 있다. Examples of typical natural materials with anti-neurodegenerative effects include sizzindrin, gastrodine, quercetin, and schizandrin are known as Schisandra As a functional ingredient contained in chinensis (Turcz.) Baill, inhibition of apoptosis of cerebral cortical cells induced by glutamate (Molecules, 18, 354-372, 2012 etc.), by β-amyloid Induced immunosuppressive effect (Phytotherapy Research, 25, 435-443, 2011), anti-inflammatory effect (International immunopharmacology, 17, 415-426, 2013) , 1136-1140, 2006) have been reported to prevent neurodegenerative diseases including dementia.
또한, 가스트로딘(gastrodin)은 천마(Gastrodia elata)에 함유되어 있는 주요 성분으로서, 글루타메이트에 의해 유도된 세포자살의 억제 (Cellular and molecular neurobiology, 34, 591-602, 2014), β-아밀로이드에 의해 유도된 신경독성의 억제(Brain research, 1482, 13-21, 2012), MPP+에 의해 유도된 산화적 스트레스의 보호(Neurochemistry international, 75, 79-88, 2014), LPS에 의해 유도된 염증반응의 억제 효과(PloS one, 6, e21891, 2011) 등이 입증되었다. In addition, gastrodin is a major component contained in Gastrodia elata, which inhibits glutamate-induced apoptosis (Cellular and molecular neurobiology, 34, 591-602, 2014), by β-amyloid Induced neurotoxicity (Brain research, 1482, 13-21, 2012), protection of oxidative stress induced by MPP + (Neurochemistry international, 75, 79-88, 2014), inhibition of LPS induced inflammation (PloS one, 6, e21891, 2011) have been proven.
한편, 퀘세틴(quercetin)은 많은 과일이나 식물의 잎에 포함되어 있는 플라보노이드의 일종으로서, 항산화 작용(Pharmacological research, 51, 117-123, 2005 등), 항암(Anticancer research, 26, 1177-1181, 2006; Apoptosis, 12, 411-421, 2007 등), 항염증(Atherosclerosis, 218, 44-52, 2011) 효과 등이 있다고 알려져 있다. Quercetin, on the other hand, is a type of flavonoid that is contained in many fruit or plant leaves. It is known as an antioxidant (Pharmacological research, 51, 117-123, 2005), anticancer research (26, 1177-1181, 2006; Apoptosis, 12, 411-421, 2007) and anti-inflammatory effects (Atherosclerosis, 218, 44-52, 2011).
뿐만 아니라, β-아밀로이드 1-42에 의해 유도된 세포독성 억제(The Journal of nutritional biochemistry, 20, 269-275, 2009), 과산화수소에 의해 유도된 세포사멸 억제(Neuroscience letters, 504, 223-227, 2011), NO와 iNOS의 형성을 억제함으로써 6-OHDA에 의해 유도된 신경세포 독성 완화 효과(International journal of molecular medicine, 27, 195-203, 2011)에 의해 신경퇴행성 질환에도 효능이 있는 것으로 알려져 있다. In addition, inhibition of cytotoxicity induced by? -Amyloid 1-42 (The Journal of nutritional biochemistry, 20, 269-275, 2009), inhibition of cell death induced by hydrogen peroxide (Neuroscience letters, 504, 223-227, 2011), it is known that 6-OHDA-induced neurotoxicity mitigation effects by inhibiting the formation of NO and iNOS (International Journal of Molecular Medicine, 27, 195-203, 2011) .
본 발명의 상기 항신경변성 천연물 소재의 스크리닝 방법에서, 상기 마우스 유래 해마신경세포는 HT-22 세포일 수 있다.In the screening method for the anti-neural degenerate natural material of the present invention, the mouse-derived hippocampal neuron may be HT-22 cells.
본 발명의 상기 항신경변성 천연물 소재의 스크리닝 방법에서, 상기 천연물 소재는 시잔드린 또는 퀘세틴이고, 상기 농도가 0.1~10μM, 바람직하게는 1~10μM, 보다 바람직하게는 5~10μM, 가장 바람직하게는 5μM일 수 있다. In the method for screening the anti-neuronigenic natural material of the present invention, the natural material is isozinc or quercetin, and the concentration is 0.1 to 10 μM, preferably 1 to 10 μM, more preferably 5 to 10 μM, most preferably May be 5 [mu] M.
본 발명의 상기 항신경변성 천연물 소재의 스크리닝 방법에서, 상기 천연물 소재는 가스트로딘이고, 상기 농도가 0.1~1μM, 바람직하게는 0.5~1μM, 가장 바람직하게는 1μM일 수 있다.In the method for screening the anti-neural degenerate natural material of the present invention, the natural material may be gastron, and the concentration may be 0.1-1 μM, preferably 0.5-1 μM, and most preferably 1 μM.
본 발명의 상기 항신경변성 천연물 소재의 스크리닝 방법에서, 상기 응집율은 하기의 식 1에 의해 계산될 수 있다.In the screening method of the anti-neural degenerate natural material of the present invention, the coagulation ratio can be calculated by the following equation (1).
[식 1][Formula 1]
TDP-43의 응집율 (%) = (세포질내에 존재하는 TDP-43 단백질 응집 세포수/전체 세포수) × 100Coagulation ratio (%) of TDP-43 = (number of TDP-43 protein aggregated cells / total number of cells present in cytoplasm) × 100
본 발명의 상기 항신경변성 천연물 소재의 스크리닝 방법에서, 상기 (b) 단계의 스크리닝은 대조군의 응집율과 대비하여, 상기 TDP-43의 응집율이 50% 이상 낮은 천연물 소재를 선별하는 것일 수 있다.In the screening method for the anti-neuronigenic natural material of the present invention, the screening in the step (b) may be performed by selecting a natural material having an aggregation ratio of TDP-43 of 50% or more as compared to the aggregation rate of the control group .
본 발명의 상기 항신경변성 천연물 소재의 스크리닝 방법에서, 상기 대조군은 프로테아좀 저해제(proteasome inhibitor), 바람직하게는 MG-132를 처리한 것일 수 있다.In the screening method for the anti-neural degenerate natural material of the present invention, the control group may be a proteasome inhibitor, preferably MG-132.
또한, 본 발명은 상기의 방법에 의해 스크리닝된 천연물 소재에 관환 것이다.The present invention also relates to a natural material screen screened by the above method.
본 발명의 상기 천여물 소재에서 상기 소재는 가스트로딘, 시잔드린 및 퀘세틴으로 이루어진 군에서 선택되는 1종 이상일 수 있다.In the present invention, the material may be at least one selected from the group consisting of gastrodine, sizandrine, and quercetin.
이하 본 발명의 내용을 실시예 및 시험예를 통하여 구체적으로 설명한다. 그러나, 이들은 본 발명을 보다 상세하게 설명하기 위한 것으로 본 발명의 권리범위가 이들에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples and Test Examples. However, these are for the purpose of illustrating the present invention in more detail, and the scope of the present invention is not limited thereto.
<실시예><Examples>
1. 실험재료1. Experimental material
(1). 재료(One). material
가스트로딘 (gastrodin)은 Biopurity (Biopurity phytochemicals Ltd. China)구입하였으며, 시잔드린 (schizandrin)은 Korea Traditional Medical Industry (Gyeongsan, S. Korea)에서 구입하여 사용하였다. Gastrodin was purchased from Biopurity (Biopurity phytochemicals Ltd. China), and schizandrin was purchased from Korea Traditional Medical Industry (Gyeongsan, S. Korea).
퀘세틴 (quercetin)과 MG-132는 Sigma-Aldrich (Saint Louis, MO)에서 구입하여 사용하였다.Quercetin and MG-132 were purchased from Sigma-Aldrich (Saint Louis, Mo.).
(2). 세포주(2). Cell line
HT-22세포는 마우스 유래의 해마신경세포로 Salk institute (La Jolla, CA, USA)에서 분양받아 사용하였다.HT-22 cells were harvested from mouse-derived hippocampal neurons using the Salk institute (La Jolla, CA, USA).
2. 실험방법2. Experimental Method
(1). 세포 배양 및 분화(One). Cell culture and differentiation
실험에 이용하는 신경세포는 마우스 유래의 해마신경세포(Hippocampal cell line, HT-22)로 Salk institute (USA)에서 분양받아 사용하였다. Dulbecdo's modified Eagle's medium (DMEM)에 10% 소태아 혈청(FBS), 1% 페니실린-스트렙토마이신을 이용하여 37℃, 5% CO2의 조건에서 배양하였다. The nerve cells used in the experiments were hippocampal cell line (HT-22) derived from mouse and were used in Salk institute (USA). Were cultured in Dulbecco's modified Eagle's medium (DMEM) at 37 ° C and 5% CO 2 with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin.
배양은 3일 간격으로 하고, 세포는 플레이트 바닥에 80% 융합(confluent) 상태에서 인산완충 식염수(PBS)로 세척한 뒤, 0.05% 트립신-EDTA 용액을 넣어 정치시킨 후, 세포를 떼어낸 다음, 계대 배양하여 유지하였다.The cells were incubated at 3-day intervals. The cells were washed with phosphate-buffered saline (PBS) at 80% confluent on the bottom of the plate, allowed to stand with 0.05% trypsin-EDTA solution, Followed by subculture.
HT-22 세포는 NeuroBasal 배지에 2 mM 글루타민, 1X N2, 100 μM 6,2'-O-Dibutyryladenosine 3',5'-cyclic monophosphate sodium salt를 첨가한 분화유도 배지로 교체하여 24시간 동안 배양하여 분화를 유도하였다.HT-22 cells were cultured in NeuroBasal medium for 24 hours after replacing with differentiation induction medium supplemented with 2 mM glutamine, 1 × N 2 , 100 μM 6,2'-O-Dibutyryladenosine 3 ', 5'-cyclic monophosphate sodium salt Differentiation was induced.
(2). 천연물 소재 세포생존율 측정(2). Cell survival rate measurement of natural material
세포를 96-웰 플레이트에 각각 5×104 세포/웰 100㎕ 분주하여, 24시간 5% CO2, 37℃에서 배양하였다. 세포 배양액에 각각의 시료를 농도별로 처리한 뒤, 시간별로 배양하였다. Cells were plated at 5 × 10 4 cells / well in a 96-well plate, and cultured at 37 ° C. for 24 hours at 5% CO 2 . The cells were treated with each sample in a concentration-dependent manner, and then cultured for a period of time.
배지와 처리시료를 모두 제거한 뒤, PBS 100㎕와 CCK-8 10㎕를 처리한 다음, 5% CO2, 37℃에서 2시간 동안 반응시켰다. 10㎕ 1 N HCl로 반응을 정지시키고 450 nm에서 흡광도를 측정하였다. After removing both the medium and the treated samples, 100 μl of PBS and 10 μl of CCK-8 were treated, followed by reaction at 37 ° C in 5% CO 2 for 2 hours. The reaction was stopped with 10 μl 1 N HCl and the absorbance at 450 nm was measured.
무처리 대조구와 시료를 처리한 실험군의 비율을 계산하여 농도별 시료 처리로 인한 세포 성장저해 효과를 비교하였다.The inhibitory effects of cell - growth inhibition were studied by calculating the ratios of the untreated control and the treated groups.
(3). 면역염색 형광 이미지 평가(3). Immunostaining fluorescent image evaluation
10μg/ml 폴리-L-오르니친과 10μg/ml 라미닌으로 코팅한 커버슬립(coverslip)에 세포를 접종하였다. 37℃, 5% CO2, 24시간 배양한 후, 위에서 언급한 것과 같이 분화를 유도한 다음, 24시간 배양하였다. Cells were inoculated on a coverslip coated with 10 [mu] g / ml poly-L-ornithine and 10 [mu] g / ml laminin. After incubation at 37 ° C and 5% CO 2 for 24 hours, differentiation was induced as described above, followed by culturing for 24 hours.
가스트로딘 외 2종의 기능성 성분을 각각 처리하고, 12시간 뒤 MG-132(프로테아좀 억제제) 1μ을 처리한 후 2시간 동안 배양하였다. 배양이 끝난 후, 4% 파라포름알데히드를 이용하여 세포를 고정하였다. Gastrodine, and the other two functional components were treated with MG-132 (proteasome inhibitor) 1 μl for 12 hours, followed by culturing for 2 hours. After incubation, the cells were fixed with 4% paraformaldehyde.
그리고 나서 PBS로 세척 후, 블로킹 용액(0.4% BSA, 0.2% 트리톤X-100 및 10% 닭 혈청, PBS)를 이용하여 2시간 동안 블로킹을 실시하였다. 확인하고자 하는 단백질의 1차 항체 (TDP-43, EdU)를 블로킹 용액에 용해하여 세포에 4℃에서 12시간 이상 처리하였다. Then, the cells were washed with PBS, and then blocked for 2 hours using a blocking solution (0.4% BSA, 0.2% Triton X-100 and 10% chicken serum, PBS). The primary antibody (TDP-43, EdU) of the protein to be identified was dissolved in the blocking solution and treated at 4 ° C for 12 hours or longer.
PBS로 세척한 뒤, 2차 항체(Alexa Flour® 488-conjuated chicken anti-mouse IgG 또는 Alexa Flour® 594 conjugated chicken anti-rabbit IgG)와 4',6-디아미디노-2-페닐인돌, 디락테이트(DAPI, 핵염색)를 이용하여 2시간 동안 실온에서 세포를 염색하였다. After washing with PBS, 2 secondary antibody (Alexa Flour ® 488-conjuated chicken anti-mouse IgG or Alexa Flour ® 594 conjugated chicken anti- rabbit IgG) with 4 ', 6-dia mi dino-2-phenyl-indole, Dirac Tate (DAPI, nuclear staining) for 2 hours at room temperature.
PBS로 세척한 뒤, FluoromountTM aqueous mounting medium를 이용하여 커버슬립을 현미경 슬라이드에 붙인 뒤, 형광 현미경을 통해 이미지화하였다. After washing with PBS, Fluoromount TM Cover slips were attached to microscope slides using an aqueous mounting medium and imaged via fluorescence microscopy.
전체 세포 중 세포질 내 TDP-43 단백질 응집 현상을 보이는 세포의 비율을 하기 식 1에 의해 계산하여 기능성 성분의 TDP-43 응집 억제 효과를 비교하였다.The ratio of cells exhibiting TDP-43 protein aggregation in the cytoplasm of all cells was calculated by the following
[식 1][Formula 1]
TDP-43의 응집율 (%) = (세포질내에 존재하는 TDP-43 단백질 응집 세포수/전체 세포수) × 100Coagulation ratio (%) of TDP-43 = (number of TDP-43 protein aggregated cells / total number of cells present in cytoplasm) × 100
(4). (4). TDPTDP -43 단백질 항원-항체반응 검증 평가-43 protein antigen-antibody reaction validation evaluation
10cm의 플레이트에 세포를 접종 한 뒤, 37℃, 5% CO2, 24시간 동안 배양하였다. 가스트로딘 외 2종의 기능성 성분을 각각 처리하고, 12시간 후에 MG-132 (프로테아좀 저해제) 1μM를 처리한 후 2시간 동안 배양하였다. Cells were inoculated on a 10-cm plate and cultured at 37 ° C, 5% CO 2 for 24 hours. And gastrodine were treated respectively. After 12 hours, 1 μM of MG-132 (proteasome inhibitor) was treated and cultured for 2 hours.
배양이 끝난 세포를 모두 회수하여 NE-PER® 핵 및 세포질 추출시약(nuclear and cytoplasmic extraction reagents)으로 세포의 핵과 세포질 단백질을 분리하여 추출한 후, 10μg의 단백질을 10% 소디움 도데실설페이트 폴리아크릴아미드 겔에 로딩하여 100V의 전압으로, 1시간 40분 동안 전기영동을 실시하였다. After the culture, all of the cells were collected, and the nucleus and cytoplasmic proteins of the cells were separated and extracted with NE-PER ® nuclear and cytoplasmic extraction reagents. Then, 10 μg of protein was dissolved in 10% sodium dodecyl sulfate polyacrylamide gel And electrophoresis was carried out at a voltage of 100 V for 1 hour and 40 minutes.
분리된 단백질을 니트로셀룰로오즈 막에 100V에서 1시간 동안 트랜스퍼를 실시하였다. 그리고 나서 상기 니트로셀룰로오즈 막을 5% 스킴 밀크를 포함하는 PBST 용액을 이용하여 블로킹한 후, 1차 항체 (TDP-43, Lamin B1, GAPDH)에 4℃에서 12시간 이상 반응시켰다. The separated proteins were transferred to a nitrocellulose membrane at 100 V for 1 hour. Then, the nitrocellulose membrane was blocked with a PBST solution containing 5% skim milk, and then reacted with the primary antibody (TDP-43, Lamin B1, GAPDH) at 4 ° C for 12 hours or longer.
그런 다음, PBS로 세척한 후, 2차 항체 (goat anti-rabbit IgG-HRP)에 2시간 동안 실온에서 반응시킨 뒤 PBS로 세척하였다. 화학발광 검출키트(chemiluminescence detection kit)와 X-레이 필름을 이용하여 암실에서 막을 현상하였다. After washing with PBS, the cells were reacted with a secondary antibody (goat anti-rabbit IgG-HRP) for 2 hours at room temperature and washed with PBS. The film was developed in a dark room using a chemiluminescence detection kit and an X-ray film.
세포질 및 핵 내의 TDP-43 단백질 발현량을 처리군 별로 비교하여 기능성 성분의 TDP-43 단백질 응집 억제 효과를 분석하였다.The expression level of TDP-43 protein in the cytoplasm and nucleus was compared among the treatment groups to analyze the inhibitory effect of the functional component on TDP-43 protein aggregation.
(5). 통계 처리(5). Statistical processing
통계 처리는 SAS 9.0(SAS Institute Ins., SAS Campus Drive, Cary, North carolina 27513, USA)를 이용하여 분산 분석을 실시하여 Duncan's multiple range test (p<0.05)를 통해 유의차를 검증하였다. Statistical analysis was performed using SAS 9.0 (SAS Institute Inc., SAS Campus Drive, Cary, North Carolina 27513, USA) and Duncan's multiple range test (p <0.05).
3. 결과 및 고찰3. Results and Discussion
(1). 천연물 소재 해마신경세포 생존율 평가(One). Assessment of hippocampal neuron survival rate of natural material
본 발명에서 사용된 천연물 소재들의 해마신경세포의 생존에 미치는 영향을 알아보기 위하여, 마우스 유래 HT-22 세포에 가스트로딘, 시잔드린 및 퀘세틴을 0~10 μM까지 농도별로 처리한 후, 48시간 동안 배양하여 세포 생존율을 측정한 결과를 도 1에 나타내었다. In order to examine the effect of the natural materials used in the present invention on the survival of hippocampal neurons, mouse-derived HT-22 cells were treated with 0 to 10 μM of gastrodine, And the cell viability was measured. The results are shown in Fig.
도 1에서 보는 바와 같이, 시잔드린과 퀘세틴의 경우, 0.1~10μM의 농도 범위에서 130~150% 수준으로 세포 성장을 촉진시켰으며, 5μM의 농도에서 가장 높은 세포 성장율을 보였다. As shown in FIG. 1, in the case of sizadrine and quercetin, the cell growth was promoted to a level of 130 to 150% at a concentration range of 0.1 to 10 μM, and the highest cell growth rate was observed at a concentration of 5 μM.
반면에, 가스트로딘의 경우, 0.1~1 μM의 농도 범위에서는 세포 성장을 촉진시켰으나, 5μM 이상의 농도에서는 세포 생존율을 60% 이상 감소시켰다. On the other hand, in the case of gastrodine, the cell growth was accelerated in the concentration range of 0.1 to 1 μM, but the cell survival rate was decreased by more than 60% at the concentration of 5 μM or more.
이러한 결과를 통하여, 해마신경세포의 생존률에 영향을 미치지 않는 천연물 소재의 최고 농도를 결정하여 TDP-43 단백질 축적 억제 평가를 수행하였다.From these results, we evaluated the inhibition of TDP-43 protein accumulation by determining the highest concentration of natural material that does not affect the viability of hippocampal neurons.
(2). (2). TDPTDP -43 세포면역 염색 형광 이미지 평가-43 Cell Immunostaining Fluorescence image evaluation
TDP-43 단백질은 정상 신경세포에서는 주로 핵내에 위치하지만, MG-132와 같은 프로테아좀 저해제를 처리하면 TDP-43 단백질은 세포질 내에 축적되어 응집물을 형성한다. The TDP-43 protein is mainly located in the nucleus of normal neurons, but when treated with a proteasome inhibitor such as MG-132, the TDP-43 protein accumulates in the cytoplasm and forms aggregates.
그러므로, 해마신경세포(HT-22) 세포질내의 TDP-43 응집을 유도하여 TDP-43 응집 억제 효과를 평가할 수 있는 MG-132의 농도를 결정하였다. Therefore, we determined the concentration of MG-132, which can induce TDP-43 aggregation inhibition in hippocampal neurons (HT-22) cytoplasm by assessing TDP-43 aggregation inhibition.
이 결과, MG-132 1μM을 처리했을 때, 핵내의 TDP-43 단백질이 세포질 밖으로 빠져 나오는 것을 확인하였다 (30% 이상 TDP-43 응집을 유도). As a result, when treated with 1 μM of MG-132, it was confirmed that the TDP-43 protein in the nucleus disappeared from the cytoplasm (inducing TDP-43 aggregation of 30% or more).
본 발명에서 사용된 천연물 소재들의 해마신경세포의 세포질내 TDP-43 응집 억제 형광 이미지 평가를 실시한 결과, 도 2에서 보는 바와 같이, 가스트로딘 1μM에 대한 TDP-43 단백질 축적은 약간 감소한 것으로 보이지만, MG-132만을 처리한 대조군과 유의적 차이는 보이지 않았다 (MG-132 유도 세포 대비 TDP-43 응집 유도 억제 효과율=약 23.5%) (p<0.05). As shown in FIG. 2, the accumulation of TDP-43 protein in 1 μM of gastrointin was slightly decreased, but the activity of MG There was no significant difference between the control group treated with -132 (MG-132 induced cells and TDP-43 aggregation-induced inhibitory effect = 23.5%) (p <0.05).
도 2에서, A는 HT-22 세포의 TDP-43 면역반응성 이미지를 나타낸 것으로서, 이때 MG-132 및 가스트로딘의 처리 농도는 각각 1μM이었다. 또한, 도 2에서 B는 TDP-43의 응집율을 나타낸 것이다.In FIG. 2, A shows the TDP-43 immunoreactive image of HT-22 cells, wherein the treatment concentrations of MG-132 and gastronin were 1 μM, respectively. In Fig. 2, B represents the coagulation ratio of TDP-43.
이상으로부터 항신경변성 효과가 있는 가스트로딘 천연물 소재는 해마신경세포의 세포질내 TDP-43 단백질 축적 억제효과는 없거나 미미한 수준으로 판단되었다. From these results, it was concluded that Gastrodine natural material, which has anti-neurodegenerative effect, has little or no inhibitory effect on TDP-43 protein accumulation in cytoplasm of hippocampal neurons.
시잔드린과 퀘세틴의 경우, 가스트로딘 보다는 해마신경세포에 대해 독성이 적고, 세포 생존률이 가장 높은 5μM 농도에 대한 TDP-43 단백질 축적억제 효과를 평가하였다. In the case of sizandrine and quercetin, the inhibitory effect of TDP-43 protein accumulation on the hippocampal neuronal cell was evaluated at a concentration of 5 μM, which is less toxic to hippocampal neurons and has the highest cell survival rate.
도 3에서 보는 바와 같이, 시잔드린의 경우, TDP-43 단백질 축적은 15.6±3.1%이였으며, MG-132만을 처리한 대조군에 비해 약 50%가 유의적으로 감소한(p<0.05) 결과로, 이는 in vitro 형광 이미지 평가법으로 다양한 천물물 소재들 중 TDP-43 단백질 타겟 항신경변성 천연물 소재를 신속히 스크리닝할 수 있는 기준으로 가능성을 제시한 결과로 판단된다. As shown in FIG. 3, the TDP-43 protein accumulation was 15.6 ± 3.1% in case of iszanidin, and the decrease was about 50% (p <0.05) as compared with the MG- This result suggests that the possibility of rapid screening of TDP-43 protein target antineutrophiligenic natural material among various materials by using in vitro fluorescence image evaluation method is suggested.
도 3에서, A는 HT-22 세포의 TDP-43 면역반응성 이미지를 나타낸 것으로서, 이때 MG-132의 처리 농도는 1μM이었고, 시잔드린의 처리 농도는 5μM이었다. 또한, 도 3에서 B는 TDP-43의 응집율을 나타낸 것이다.In FIG. 3, A shows the TDP-43 immunoreactivity image of HT-22 cells, wherein the treatment concentration of MG-132 was 1 μM and the treatment concentration of thiazolidine was 5 μM. 3, B shows the coagulation rate of TDP-43.
한편, 도 4에서 보는 바와 같이, 퀘세틴의 TDP-43 단백질 축적은 21.5±2.8%이였으며, MG-132만을 처리한 대조군에 비해 약 33%가 감소되어 가스트로딘 보다는 TDP-43 단백질이 축적억제 효과를 보였지만, MG-132만을 처리한 대조군과는 유의적인 차이는 보이지 않았다 (p<0.05). As shown in FIG. 4, the accumulation of TDP-43 protein in quercetin was 21.5 ± 2.8%, which was about 33% lower than that of the MG-132-treated control, (P <0.05). However, there was no significant difference from the control group treated with MG-132 alone (p <0.05).
도 4에서, A는 HT-22 세포의 TDP-43 면역반응성 이미지를 나타낸 것으로서, 이때 MG-132의 처리 농도는 1μM이었고, 시잔드린의 처리 농도는 5μM이었다. 또한, 도 4에서 B는 TDP-43의 응집율을 나타낸 것이다.In FIG. 4, A shows the TDP-43 immunoreactivity image of HT-22 cells, wherein the treatment concentration of MG-132 was 1 μM and the treatment concentration of thiazolidine was 5 μM. In Fig. 4, B represents the coagulation ratio of TDP-43.
(3). (3). TDPTDP -43 단백질 항원-항체반응 검증 평가-43 protein antigen-antibody reaction validation evaluation
상기 in vitro 형광 이미지 평가법에 의하여 스크리닝된 시잔드린 소재에 대한 해마신경세포의 세포질과 핵내 TDP-43 단백질 발현량을 알아보기 위하여, 항원-항체반응 검증 평가를 실시하였다. Antibody-antibody reaction assays were performed to examine the cytoplasmic and nuclear intracellular TDP-43 protein expression levels of hippocampal neurons for sizadrine screened by in vitro fluorescence image assay.
도 5에서 보는 바와 같이, MG-132 처리에 의해 세포질 내 TDP-43 단백질의 발현량이 약 41.0±15.5% 증가하였으나, 시잔드린과 함께 세포에 처리시 세포질내의 단백질 발현량이 MG-132 무처리군(control)과 유사한 수준이었다. As shown in FIG. 5, the expression level of TDP-43 protein in the cytoplasm was increased by about 41.0 ± 15.5% by treatment with MG-132, but the amount of protein expression in cytoplasm when treated with sizzlin was not treated with MG-132 control.
이는 in vitro 형광 이미지 평가법에 의하여 TDP-43 단백질 축적억제 효과를 보이는 천연물 소재를 신속히 스크리닝할 수 있는 방법으로 유효하다는 것을 의미한다. This means that it is effective as a method for rapidly screening a natural material having an inhibitory effect on TDP-43 protein accumulation by an in vitro fluorescent image evaluation method.
도 5에서, A는 HT-22 세포로부터 라이세이트(lysates)를 이용한 TDP-43의 면역블로팅(immuno blotting) 결과로서, 이때 MG-132의 처리 농도는 1μM이었고, 시잔드린의 처리 농도는 1μM 및 5μM이었다. In FIG. 5, A is the result of immunoblotting of TDP-43 using lysates from HT-22 cells, wherein the treatment concentration of MG-132 was 1 μM and the treatment concentration of thiazolidine was 1 μM And 5 [mu] M.
또한, 도 5에서 B는 세포질내에서의 TDP-43 단백질 발현량을 나타낸 것이고, C는 핵내에서의 TDP-43 단백질 발현량을 나타낸 것이다.In FIG. 5, B represents the amount of TDP-43 protein expression in the cytoplasm, and C represents the amount of TDP-43 protein expression in the nucleus.
4. 결론4. Conclusion
(1). 본 발병에서 해마신경세포(HT-22)의 생존율 평가에 대한 천연물 소재(가스트로딘, 시잔드린, 퀘세틴)의 농도는 0.1~10 μM의 농도 범위에서 수행하였으며, 본 발병에서 사용된 대표적인 신경변성질환에 효과가 있는 천연물 소재들은 해마신경세포의 성장을 130~150% 촉진시켰다. (One). Concentrations of natural materials (gastrodine, iszandrine, quercetin) for evaluation of survival rate of hippocampal neurons (HT-22) in this outbreak were performed in the concentration range of 0.1 ~ 10 μM, and the representative neurodegeneration The natural materials that are effective for the disease promoted the growth of hippocampal neurons by 130 ~ 150%.
이에 따라, 해마신경세포를 성장시킨 천연물 소재 처리 농도 범위에서 TDP-43 단백질 응집 억제 효과를 평가하였다 (가스트로딘은 1μM, 시잔드린 5μM, 퀘세틴 5μM). TDP-43 단백질 응집 억제 효과를 평가하기 위한 천연물 소재들의 농도는 해마신경세포를 성장시키는 범위에서 결정하는 것이 좋으나, 독성이 있는 천연물 소재들에 있어서는 해마신경세포가 최소 80% 이상의 생존율이 보이는 농도가 바람직하다. Thus, the inhibitory effect of TDP-43 protein aggregation was evaluated in the concentration range of the natural material to which hippocampal neurons had been grown (1 μM of gastrodine, 5 μM of thiazolidine, and 5 μM of quercetin). In order to evaluate the effect of inhibiting TDP-43 protein aggregation, it is preferable to determine the concentration of natural materials in the range of hippocampal neuron growth. However, in the toxic natural materials, the hippocampal neuron exhibits a survival rate of at least 80% desirable.
(2). 또한, 해마신경세포(HT-22)의 세포질 내로 TDP-43 단백질 응집을 유도하기 위한 MG-132 유도제의 처리 최적 농도와 시간은 각각 1μM과 2시간으로, 해마신경세포(HT-22)의 세포질내로 TDP-43 단백질이 30% 이상 유도되는 것이 바람직하다. (2). In addition, the optimal concentration and time of MG-132 inducing agent for inducing TDP-43 protein aggregation into the cytoplasm of hippocampal neurons (HT-22) were 1 μM and 2 hours, respectively, It is preferable that the TDP-43 protein is induced by 30% or more.
(3). 해마신경세포(HT-22)의 세포질 내 TDP-43 단백질 응집 억제 효과가 있는 천연물 소재들을 신속히 선별할 수 있는 본 발명의 in vitro 형광이미지 평가법에 있어서, 50~300개의 면역형광염색이된 세포를 집계하여 MG-132 유도 대조군 대비 TDP-43 응집 억제 효과가 평균 50% 이상되는 소재들을 선별하는 것이 바람직하다. 또한 in vitro 형광이미지 평가법에서 선별된 소재들은 TDP-43 단백질 항원-항체반응 확인 단계를 수행하는 것이 바람직하다.(3). In the in vitro fluorescence image evaluation method of the present invention, in which natural material materials having hippocampal neuron cell (HT-22) inhibitory effect on TDP-43 protein aggregation in cytoplasm can be rapidly selected, 50-300 immunofluorescently stained cells It is preferable to select materials having an average TDP-43 aggregation inhibiting effect of 50% or more compared to the MG-132 induction control. In addition, it is preferable to perform the TDP-43 protein antigen-antibody reaction confirmation step in the materials selected in the in vitro fluorescence image evaluation method.
상술한 바와 같이, 본 발명의 바람직한 실시예를 참조하여 설명하였지만 해당 기술 분야의 숙련된 당업자라면 하기의 특허청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다. Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims. It will be understood that the present invention can be changed.
본 발명의 신경변성 천연물 소재의 스크리닝 방법은 in vitro에서 해마신경세포의 세포질내 TDP-43 단백질 응집억제 효과가 있는 천연물 소재들을 신속히 선별할 수 있는 방법을 제공할 수 있기 때문에, 본 발명이 속하는 기술분야에 유용하게 적용될 수 있다.Since the screening method of the neurodegenerative natural material of the present invention can provide a method for rapidly selecting natural material having the effect of suppressing TDP-43 protein aggregation in the cytoplasm of hippocampal neurons in vitro, It can be usefully applied to the field.
Claims (10)
(b). 상기 결정된 천연물 소재의 농도에 대한 상기 해마신경세포의 세포질내에 존재하는 트랜스액티브 리스폰스 DNA-결합 단백질 43(TDP-43)의 응집율을 평가하여, 천연물 소재를 스크리닝하는 단계; 및
(c). 항원-항체반응을 이용하여, 상기 스크리닝된 천연물 소재에 대한 해마신경세포의 세포질 및 핵내의 TDP-43 발현량을 평가하는 단계를 포함하는, 항신경변성 천연물 소재의 스크리닝 방법.(a). Determining the concentration of the natural product material that does not affect the viability of the hippocampal neuron by evaluating the survival rate of the mouse derived hippocampal neuron with respect to the natural product material, wherein the natural product material is gastrodine, sizandrine, or quercetin , The concentration of thymindrine or quercetin is 0.1 to 10 μM, and the concentration of gastronine is 0.1 to 1 μM;
(b). Evaluating the aggregation rate of the transcriptional response DNA-binding protein 43 (TDP-43) present in the cytoplasm of the hippocampal neuron to the determined concentration of the natural material, and screening the natural material; And
(c). And evaluating the amount of TDP-43 expression in the cytoplasm and nucleus of hippocampal neuron cells against the screened natural material using an antigen-antibody reaction.
[식 1]
TDP-43의 응집율 (%) = (세포질내에 존재하는 TDP-43 단백질 응집 세포수/전체 세포수) × 1002. The method for screening anti-neuronigenic natural material according to claim 1, wherein the coagulation ratio is calculated by the following formula 1:
[Formula 1]
Coagulation ratio (%) of TDP-43 = (number of TDP-43 protein aggregated cells / total number of cells present in cytoplasm) × 100
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160029678A KR101922903B1 (en) | 2016-03-11 | 2016-03-11 | Method for screening natural product-derived antineurodegenerative ingredients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160029678A KR101922903B1 (en) | 2016-03-11 | 2016-03-11 | Method for screening natural product-derived antineurodegenerative ingredients |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170106052A KR20170106052A (en) | 2017-09-20 |
KR101922903B1 true KR101922903B1 (en) | 2018-11-28 |
Family
ID=60034178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160029678A Expired - Fee Related KR101922903B1 (en) | 2016-03-11 | 2016-03-11 | Method for screening natural product-derived antineurodegenerative ingredients |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101922903B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008527002A (en) | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ, インコーポレイテッド | Novel composition for preventing and treating neurodegenerative disorders and blood coagulation disorders |
KR100882325B1 (en) * | 2007-06-19 | 2009-02-11 | 무주군약초영농조합법인 | Processing method of Cheonma to increase the content of gastrodine, an anticonvulsant |
US20110053857A1 (en) | 2008-02-15 | 2011-03-03 | Whitehead Institute For Biomedical Research | Yeast cells expressing tar dna-binding protein 43 and uses therefor |
JP2014171425A (en) * | 2013-03-08 | 2014-09-22 | Shiga Univ Of Medical Science | Screening method of compound for therapy and/or prevention of tdp-43 agglomerate-accumulating disease |
JP2014196268A (en) | 2013-03-29 | 2014-10-16 | 公益財団法人東京都医学総合研究所 | Pharmaceutical composition for therapy or prevention of neurodegenerative disease, comprising fulvestrant |
JP2015506905A (en) | 2012-01-17 | 2015-03-05 | 国立大学法人京都大学 | Prophylactic and therapeutic agent for amyotrophic lateral sclerosis and screening method thereof |
-
2016
- 2016-03-11 KR KR1020160029678A patent/KR101922903B1/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008527002A (en) | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ, インコーポレイテッド | Novel composition for preventing and treating neurodegenerative disorders and blood coagulation disorders |
KR100882325B1 (en) * | 2007-06-19 | 2009-02-11 | 무주군약초영농조합법인 | Processing method of Cheonma to increase the content of gastrodine, an anticonvulsant |
US20110053857A1 (en) | 2008-02-15 | 2011-03-03 | Whitehead Institute For Biomedical Research | Yeast cells expressing tar dna-binding protein 43 and uses therefor |
JP2015506905A (en) | 2012-01-17 | 2015-03-05 | 国立大学法人京都大学 | Prophylactic and therapeutic agent for amyotrophic lateral sclerosis and screening method thereof |
JP2014171425A (en) * | 2013-03-08 | 2014-09-22 | Shiga Univ Of Medical Science | Screening method of compound for therapy and/or prevention of tdp-43 agglomerate-accumulating disease |
JP2014196268A (en) | 2013-03-29 | 2014-10-16 | 公益財団法人東京都医学総合研究所 | Pharmaceutical composition for therapy or prevention of neurodegenerative disease, comprising fulvestrant |
Non-Patent Citations (5)
Title |
---|
Evidence-Based Complementary and Alternative Medicine(2015), vol.2015, ID 393510, pp. 1-17. |
Janet van Eersel et al, PLOS ONE (2011), vol. 6, no. 7, e22850-1~13. |
Justin D. Boyd et al, J Biomol Screen (2014), vol. 19, no. 1, pp. 44-56. |
The Journal of Clinical Investigation(2014), vol.124(4), pp. 1821-1834. |
이혜지 저., 천연물 소재의 항암효과 및 항신경변성 효과 분석, 전북대학교 식품공학과 석사학위 논문(2016.02.), pp. 1-72. |
Also Published As
Publication number | Publication date |
---|---|
KR20170106052A (en) | 2017-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Eriodictyol ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via vitamin D receptor-mediated Nrf2 activation | |
Wang et al. | Resveratrol attenuates oxidative damage through activating mitophagy in an in vitro model of Alzheimer’s disease | |
Liu et al. | KIF5A-dependent axonal transport deficiency disrupts autophagic flux in trimethyltin chloride-induced neurotoxicity | |
Wang et al. | The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons | |
Lu et al. | Formaldehyde induces hyperphosphorylation and polymerization of Tau protein both in vitro and in vivo | |
Kwon et al. | Involvement of the Nrf2/HO-1 signaling pathway in sulfuretin-induced protection against amyloid beta25–35 neurotoxicity | |
Bendotti et al. | Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response | |
Wang et al. | Fucoidan inhibits amyloid-β-induced toxicity in transgenic Caenorhabditis elegans by reducing the accumulation of amyloid-β and decreasing the production of reactive oxygen species | |
Sishi et al. | Doxorubicin induces protein ubiquitination and inhibits proteasome activity during cardiotoxicity | |
Yan et al. | Overexpression of human E46K mutant α-synuclein impairs macroautophagy via inactivation of JNK1-Bcl-2 pathway | |
Huang et al. | High glucose induces activation of NF-κB inflammatory signaling through IκBα sumoylation in rat mesangial cells | |
Lu et al. | Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line | |
Mo et al. | GPR39 protects against corticosterone-induced neuronal injury in hippocampal cells through the CREB-BDNF signaling pathway | |
Epelbaum et al. | Acute amnestic encephalopathy in amyloid-β oligomer–injected mice is due to their widespread diffusion in vivo | |
Li et al. | DLP 1‐dependent mitochondrial fragmentation and redistribution mediate prion‐associated mitochondrial dysfunction and neuronal death | |
Yuen et al. | Danshen (Salvia miltiorrhiza) water extract shows potential neuroprotective effects in Caenorhabditis elegans | |
Pinkaew et al. | Di-O-demethylcurcumin protects SK-N-SH cells against mitochondrial and endoplasmic reticulum-mediated apoptotic cell death induced by Aβ25-35 | |
Kato et al. | Niclosamide affects intracellular TDP-43 distribution in motor neurons, activates mitophagy, and attenuates morphological changes under stress | |
Henrı́quez et al. | Neuroprotective effect of brazilin on amyloid β (25–35)-induced pathology in a human neuroblastoma model | |
Kumkarnjana et al. | Flavonoids kaempferide and 4, 2′-dihydroxy-4′, 5′, 6′-trimethoxychalcone inhibit mitotic clonal expansion and induce apoptosis during the early phase of adipogenesis in 3T3-L1 cells | |
Chhangani et al. | Mahogunin ring finger 1 confers cytoprotection against mutant SOD1 aggresomes and is defective in an ALS mouse model | |
Nuber et al. | The Parkinson-associated toxin paraquat shifts physiological α-synuclein tetramers toward monomers that can be calpain-truncated and form oligomers | |
Yang et al. | Sulforaphane attenuates microglia-mediated neuronal damage by down-regulating the ROS/autophagy/NLRP3 signal axis in fibrillar Aβ-activated microglia | |
Yang et al. | Ginsenoside Rb2 suppresses cellular senescence of human dermal fibroblasts by inducing autophagy | |
Hofni et al. | Renoprotective Effect of thymoquinone against streptozotocin-induced diabetic nephropathy: Role of NOX2 and Nrf2 signals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20160311 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20171128 Patent event code: PE09021S01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180226 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20180821 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20181122 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20181123 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20221004 Start annual number: 5 End annual number: 5 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20240903 |